Phase 4
N=222
Interventions for Children With Attention and Reading Disorders
Attention Deficit Hyperactivity Disorder · Reading Disabilities
Bottom Line
View on ClinicalTrials.gov: NCT01133847 ↗Enrolled (actual)
222
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Inattention — 1.1; 1.7; 1.0; 1.3 Units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Methylphenidate (Drug); Intensive reading instruction (Behavioral); Parent Training (Behavioral); Mixed Salt Amphetamine (Drug); Atomoxetine (Drug); Guanfacine (Drug)
- Age
- Pediatric · 7+ yrs
- Sex
- All
- Sponsor
- The University of Texas Health Science Center, Houston
- Primary completion
- Jun 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Inattention |
1.1; 1.7; 1.0; 1.3; 1.6; 1.0 | — |
| PRIMARY Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Hyperactivity-impulsivity |
0.8; 1.3; 0.6; 0.9; 1.4; 0.7 | — |
| PRIMARY Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Inattention |
1.2; 1.7; 1.4; 1.5; 1.9; 1.5 | — |
| PRIMARY Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Hyperactivity-impulsivity |
0.7; 1.1; 0.8; 0.8; 1.1; 0.8 | — |
| PRIMARY Wechsler Individual Achievement Test-III (WIAT-III) Word Reading Subtest |
76.9; 79.0; 79.9; 77.1; 78.1; 78.8 | — |
| PRIMARY Wechsler Individual Achievement Test-III (WIAT-III) Pseudoword Decoding Subtest |
78.3; 83.8; 83.0; 77.1; 82.6; 81.9 | — |
| SECONDARY Wechsler Individual Achievement Test-III (WIAT-III) Reading Comprehension Subtest |
88.27; 84.70; 86.35 | — |
| SECONDARY Dynamic Indicators of Basic Early Literacy Skills Oral Reading Fluency Subtest (DIBELS ORF) |
53.67; 50.71; 53.83; 63.06; 57.40; 59.05 | — |
| SECONDARY Test of Word Reading Efficiency (TOWRE) - Sight Word Efficiency |
80.8; 82.7; 83.5; 83.57; 85.04; 84.15 | — |
| SECONDARY Test of Word Reading Efficiency (TOWRE) - Phonemic Decoding Efficiency |
80.4; 83.4; 82.9; 81.49; 84.50; 84.32 | — |
| SECONDARY Test of Silent Reading Fluency and Comprehension (TOSREC) |
17.40; 17.70; 18.57 | — |
Summary
The objective of this randomized clinical trial is to address unanswered questions about the relative effectiveness of treatments for children with both Attention Deficit Hyperactivity Disorder (ADHD) and significant reading difficulties (RD). The study evaluates attentional and word reading outcomes for students with both conditions when provided with either (a) ADHD treatment alone, (b) RD treatment alone, or (c) the combination of ADHD and RD treatment.
Eligibility Criteria
Inclusion Criteria
- Meet criteria for ADHD, Combined Type or ADHD, Predominantly Inattentive Type based on the Diagnostic Interview Schedule for Children, 4.0 (DISC) parent interview, Teacher baseline Swanson Nolan and Pelham Rating Scale (SNAP) endorses additional non-overlapping Inattentive symptoms with the parent DISC, which when combined with the parent ratings result in endorsement of 6 or more symptoms required for diagnosis by the Diagnostic and Statistical Manual.
- Have at least 4 symptoms of inattention rated "Often" or "Very Often" on the teacher version of the SNAP-IV.
- Have a standard score of 90 or lower on either the Woodcock-Johnson III Tests of Achievement Letter-Word Identification or Word Attack Subtests, or on the Basic Reading Skills Cluster
- Attend a participating school in Grades 2-5
- Have at least one parent or guardian who understands English well enough to participate in the behavioral parent training intervention.
- Have a Full Scale OR Non-Verbal Intelligence Quotient (IQ) estimate higher than 70 based on the IQ Composite and Non-Verbal IQ estimate of the Kaufman Brief Intelligence Test (KBIT-2).
Exclusion Criteria
- Any documented or suspected bipolar disorder, severe psychosis, or other severe emotional disturbance, developmental disability, or autism.
- Receipt of primary school reading instruction in a language other than English.
- A history or presence of cardiovascular problems that would contraindicate stimulant treatment.
- Chronic vocal tics.
- Children will be excluded if they are taking a concomitant medication that has the potential to significantly affect their ADHD symptoms, that would be contraindicated to take along with the study medication, or if they have not been on a stable dose of a psychotropic medication long enough to fully assess the clinical outcome or tolerability.
Data sourced from ClinicalTrials.gov (NCT01133847). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.